ESLA

$0.00

(

+0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Estrella Immunopharma Inc.

NASDAQ | ESLA

2.33

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 22, 2025)

$69.31M

Market Cap

-

P/E Ratio

-0.24

EPS

$2.42

52 Week High

$0.63

52 Week Low

HEALTHCARE

Sector

ESLA Chart

Recent Chart
Price Action

ESLA Technicals

Tags:

ESLA Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (None)
Gross Profit -
Total Revenue -
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$8.8M
Selling General And Administrative $1.4M
Research And Development $6.4M
Operating Expenses $8.8M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$40K
Income Before Tax -$8.8M
Income Tax Expense $1.7K
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -$8.8M
Ebitda -$8.8M
Net Income -$8.8M

Revenue & Profitability

Earnings Performance

ESLA Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (None)
Total Assets $3.1M
Total Current Assets $1.6M
Cash And Cash Equivalents At Carrying Value $917K
Cash And Short Term Investments $917K
Inventory -
Current Net Receivables $289K
Total Non Current Assets $1.5M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $724K
Other Non Current Assets -
Total Liabilities $3M
Total Current Liabilities $3M
Current Accounts Payable -
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities -
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total -
Other Current Liabilities $3M
Other Non Current Liabilities -
Total Shareholder Equity $144K
Treasury Stock -
Retained Earnings -$24M
Common Stock $3.7K
Common Stock Shares Outstanding $37M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (None)
Operating Cashflow -$7.6M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -
Capital Expenditures $1
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $5M
Cashflow From Financing -$489K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -$569K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$8.8M

yearly Income Statement (As of Dec 31, 2024)

Field Value (None)
Gross Profit -
Total Revenue -
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$8.8M
Selling General And Administrative $1.4M
Research And Development $6.4M
Operating Expenses $8.8M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$40K
Income Before Tax -$8.8M
Income Tax Expense $1.7K
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -$8.8M
Ebitda -$8.8M
Net Income -$8.8M

ESLA News

ESLA Profile

Estrella Immunopharma Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Estrella Immunopharma, Inc. is a preclinical-stage biopharmaceutical company based in Emeryville, California, focused on pioneering T-cell therapies aimed at treating blood cancers and solid tumors. With a strong commitment to advancing innovative immunotherapy solutions, Estrella seeks to address critical unmet medical needs in oncology. The company’s cutting-edge research and development efforts position it as a key player in the evolving landscape of cancer treatment, with an emphasis on harnessing the immune system to combat malignancies.

YYAI
+133.74%
$0.18
BYND
-1.10%
$3.58
YDKG
+19.92%
$0.06
BURU
+24.34%
$0.36
VHAI
0.00%
$0.00
ADAP
+49.17%
$0.07
F
-1.03%
$12.43
BENF
+205.95%
$1.49
AIRE
-1.92%
$0.71
CGBS
-39.47%
$0.03
NVDA
-0.48%
$180.28
BITF
-12.24%
$3.94
DNUT
+8.62%
$4.03
RGTI
-9.85%
$36.06
PLUG
-6.41%
$2.92
WTO
+10.81%
$0.07
DNN
0.00%
$2.72
T
-1.91%
$25.55
TLRY
-2.02%
$1.45
INTC
-3.14%
$36.92
TSLA
-0.82%
$438.97
QBTS
-15.22%
$27.29
EPWK
+13.34%
$0.08
RIG
+3.32%
$3.42
SOFI
-5.42%
$27.19
AXDX
-61.36%
$0.03
NOK
-0.53%
$5.55
ACHR
-4.82%
$10.86
CIFR
-10.87%
$16.11
RANI
-15.26%
$2.41
GPUS
+4.79%
$0.38
BBD
0.00%
$3.30
RF
-1.02%
$24.11
AMD
-3.27%
$230.23
IXHL
-2.46%
$0.34
CAN
-12.56%
$1.70
AAL
-2.10%
$12.09
QS
-12.50%
$13.58
PLTR
-3.31%
$175.49
AREB
+72.00%
$2.15
ETHD
+10.21%
$4.09
BNBX
+40.35%
$4.80
NVTS
-9.48%
$13.60
ONDS
-6.25%
$6.74
IREN
-6.09%
$51.83
NIO
+0.58%
$6.84
WBD
+0.98%
$20.53
ABEV
-0.90%
$2.20
QUBT
-7.06%
$14.87
HPE
-0.77%
$23.09
VALE
+2.21%
$11.52
ALEC
-49.84%
$1.61
PFE
-0.52%
$24.72
GRAB
+0.35%
$5.62
IONZ
+13.38%
$4.66
APLD
-5.90%
$30.62
RXRX
-5.89%
$5.75
AAPL
-1.64%
$258.45
BTBT
-7.23%
$3.59
AMZN
-1.83%
$217.95
CJET
+21.50%
$0.09
SOUN
-2.57%
$17.76
JOBY
-3.91%
$15.47
GPRO
+5.00%
$2.31
RR
-10.12%
$5.05
LAES
-11.47%
$5.40
RIVN
-2.12%
$12.92
AVDL
+3.66%
$18.52
SNAP
-1.01%
$7.77
WULF
-3.99%
$12.61
MARA
-4.58%
$19.14
UUUU
+10.22%
$22.74
RMBL
+60.50%
$3.21
IONQ
-6.80%
$55.45
SMR
-9.51%
$34.72
ADD
-25.47%
$0.05
DVLT
-15.41%
$2.14
HOOD
-3.50%
$127.22
BMNR
-7.36%
$48.03
CLSK
-10.17%
$16.86
BTG
+0.57%
$5.21
FLWS
-14.75%
$4.38
AMC
-4.84%
$2.75
GOOGL
+0.49%
$251.69
BAC
-0.81%
$51.10
SRM
+53.27%
$10.30
OKLO
-13.85%
$120.12
SMCI
-4.23%
$52.50
RGTZ
+19.73%
$18.69
VZ
-1.24%
$39.79
PBR
+1.47%
$11.73
VIVK
+7.79%
$0.24
NDLS
+33.01%
$0.95
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
UAMY
+5.81%
$13.11
GSIT
+18.69%
$12.89
ASTS
-9.23%
$71.34
JBLU
-0.85%
$4.62
EOSE
-7.60%
$15.06
YYAI
+133.74%
$0.18
BYND
-1.10%
$3.58
YDKG
+19.92%
$0.06
BURU
+24.34%
$0.36
VHAI
0.00%
$0.00
ADAP
+49.17%
$0.07
F
-1.03%
$12.43
BENF
+205.95%
$1.49
AIRE
-1.92%
$0.71
CGBS
-39.47%
$0.03
NVDA
-0.48%
$180.28
BITF
-12.24%
$3.94
DNUT
+8.62%
$4.03
RGTI
-9.85%
$36.06
PLUG
-6.41%
$2.92
WTO
+10.81%
$0.07
DNN
0.00%
$2.72
T
-1.91%
$25.55
TLRY
-2.02%
$1.45
INTC
-3.14%
$36.92
TSLA
-0.82%
$438.97
QBTS
-15.22%
$27.29
EPWK
+13.34%
$0.08
RIG
+3.32%
$3.42
SOFI
-5.42%
$27.19
AXDX
-61.36%
$0.03
NOK
-0.53%
$5.55
ACHR
-4.82%
$10.86
CIFR
-10.87%
$16.11
RANI
-15.26%
$2.41
GPUS
+4.79%
$0.38
BBD
0.00%
$3.30
RF
-1.02%
$24.11
AMD
-3.27%
$230.23
IXHL
-2.46%
$0.34
CAN
-12.56%
$1.70
AAL
-2.10%
$12.09
QS
-12.50%
$13.58
PLTR
-3.31%
$175.49
AREB
+72.00%
$2.15
ETHD
+10.21%
$4.09
BNBX
+40.35%
$4.80
NVTS
-9.48%
$13.60
ONDS
-6.25%
$6.74
IREN
-6.09%
$51.83
NIO
+0.58%
$6.84
WBD
+0.98%
$20.53
ABEV
-0.90%
$2.20
QUBT
-7.06%
$14.87
HPE
-0.77%
$23.09
VALE
+2.21%
$11.52
ALEC
-49.84%
$1.61
PFE
-0.52%
$24.72
GRAB
+0.35%
$5.62
IONZ
+13.38%
$4.66
APLD
-5.90%
$30.62
RXRX
-5.89%
$5.75
AAPL
-1.64%
$258.45
BTBT
-7.23%
$3.59
AMZN
-1.83%
$217.95
CJET
+21.50%
$0.09
SOUN
-2.57%
$17.76
JOBY
-3.91%
$15.47
GPRO
+5.00%
$2.31
RR
-10.12%
$5.05
LAES
-11.47%
$5.40
RIVN
-2.12%
$12.92
AVDL
+3.66%
$18.52
SNAP
-1.01%
$7.77
WULF
-3.99%
$12.61
MARA
-4.58%
$19.14
UUUU
+10.22%
$22.74
RMBL
+60.50%
$3.21
IONQ
-6.80%
$55.45
SMR
-9.51%
$34.72
ADD
-25.47%
$0.05
DVLT
-15.41%
$2.14
HOOD
-3.50%
$127.22
BMNR
-7.36%
$48.03
CLSK
-10.17%
$16.86
BTG
+0.57%
$5.21
FLWS
-14.75%
$4.38
AMC
-4.84%
$2.75
GOOGL
+0.49%
$251.69
BAC
-0.81%
$51.10
SRM
+53.27%
$10.30
OKLO
-13.85%
$120.12
SMCI
-4.23%
$52.50
RGTZ
+19.73%
$18.69
VZ
-1.24%
$39.79
PBR
+1.47%
$11.73
VIVK
+7.79%
$0.24
NDLS
+33.01%
$0.95
CUTR
-10.19%
$0.09
WLGS
-5.57%
$0.04
UAMY
+5.81%
$13.11
GSIT
+18.69%
$12.89
ASTS
-9.23%
$71.34
JBLU
-0.85%
$4.62
EOSE
-7.60%
$15.06
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.